Artivion, Inc. (NYSE: AORT) Stock Competitors & Peer Comparison

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ABT's P/E ratio is 20.69. In terms of profitability, AORT's ROE is -0.01%, compared to ABT's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ABT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AORT's ROE is -0.01%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, AORT is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BSX-PA's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SYK has a market cap of 130B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SYK trades at $339.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SYK's P/E ratio is 25.32. In terms of profitability, AORT's ROE is -0.01%, compared to SYK's ROE of +0.16%. Regarding short-term risk, AORT is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SYK's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while MDT trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas MDT's P/E ratio is 15.76. In terms of profitability, AORT's ROE is -0.01%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check MDT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BSX has a market cap of 73.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BSX trades at $49.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BSX's P/E ratio is 15.91. In terms of profitability, AORT's ROE is -0.01%, compared to BSX's ROE of +0.15%. Regarding short-term risk, AORT is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BSX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while EW trades at $89.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas EW's P/E ratio is 33.23. In terms of profitability, AORT's ROE is -0.01%, compared to EW's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for AORT.Check EW's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while DXCM trades at $84.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas DXCM's P/E ratio is 36.37. In terms of profitability, AORT's ROE is -0.01%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, AORT is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for AORT.Check DXCM's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while RMD trades at $211.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas RMD's P/E ratio is 19.68. In terms of profitability, AORT's ROE is -0.01%, compared to RMD's ROE of +0.24%. Regarding short-term risk, AORT is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check RMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PHG trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PHG's P/E ratio is 15.28. In terms of profitability, AORT's ROE is -0.01%, compared to PHG's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PHG's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ZBH trades at $96.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ZBH's P/E ratio is 11.38. In terms of profitability, AORT's ROE is -0.01%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AORT is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ZBH's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AORT's ROE is -0.01%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ABMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PEN trades at $324.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PEN's P/E ratio is 84.77. In terms of profitability, AORT's ROE is -0.01%, compared to PEN's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PEN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SNN trades at $30.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SNN's P/E ratio is 14.16. In terms of profitability, AORT's ROE is -0.01%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AORT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SNN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AORT's ROE is -0.01%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AORT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SWAV's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ALGN trades at $173.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ALGN's P/E ratio is 15.83. In terms of profitability, AORT's ROE is -0.01%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, AORT is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ALGN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while GMED trades at $82.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas GMED's P/E ratio is 18.56. In terms of profitability, AORT's ROE is -0.01%, compared to GMED's ROE of +0.12%. Regarding short-term risk, AORT is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for AORT.Check GMED's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while GKOS trades at $180.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas GKOS's P/E ratio is -209.45. In terms of profitability, AORT's ROE is -0.01%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, AORT is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check GKOS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PODD trades at $141.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PODD's P/E ratio is 24.05. In terms of profitability, AORT's ROE is -0.01%, compared to PODD's ROE of +0.27%. Regarding short-term risk, AORT is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PODD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BIO-B trades at $349.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, AORT's ROE is -0.01%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, AORT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BIO-B's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BIO trades at $352.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BIO's P/E ratio is 38.00. In terms of profitability, AORT's ROE is -0.01%, compared to BIO's ROE of +0.03%. Regarding short-term risk, AORT is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BIO's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas MASI's P/E ratio is 44.43. In terms of profitability, AORT's ROE is -0.01%, compared to MASI's ROE of +0.09%. Regarding short-term risk, AORT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for AORT.Check MASI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BRKR trades at $53.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BRKR's P/E ratio is 26.84. In terms of profitability, AORT's ROE is -0.01%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, AORT is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BRKR's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas NARI's P/E ratio is -59.24. In terms of profitability, AORT's ROE is -0.01%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AORT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NARI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ITGR trades at $125.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ITGR's P/E ratio is 19.72. In terms of profitability, AORT's ROE is -0.01%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, AORT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ITGR's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while IRTC trades at $127.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas IRTC's P/E ratio is -199.75. In terms of profitability, AORT's ROE is -0.01%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, AORT is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for AORT.Check IRTC's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while LIVN trades at $76.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas LIVN's P/E ratio is 18.10. In terms of profitability, AORT's ROE is -0.01%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, AORT is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check LIVN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, HAE has a market cap of 4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while HAE trades at $87.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas HAE's P/E ratio is 17.54. In terms of profitability, AORT's ROE is -0.01%, compared to HAE's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HAE's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AORT's ROE is -0.01%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AXNX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while TMDX trades at $83.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas TMDX's P/E ratio is 42.58. In terms of profitability, AORT's ROE is -0.01%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, AORT is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check TMDX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while AXGN trades at $46.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas AXGN's P/E ratio is 122.18. In terms of profitability, AORT's ROE is -0.01%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, AORT is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AXGN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while UFPT trades at $314.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas UFPT's P/E ratio is 32.07. In terms of profitability, AORT's ROE is -0.01%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AORT is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check UFPT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BFLY trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BFLY's P/E ratio is -36.77. In terms of profitability, AORT's ROE is -0.01%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, AORT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BFLY's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ESTA trades at $77.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ESTA's P/E ratio is -61.44. In terms of profitability, AORT's ROE is -0.01%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, AORT is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ESTA's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AORT's ROE is -0.01%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AORT is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NUVA's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while NVCR trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas NVCR's P/E ratio is -10.71. In terms of profitability, AORT's ROE is -0.01%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, AORT is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NVCR's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while INSP trades at $60.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas INSP's P/E ratio is 26.51. In terms of profitability, AORT's ROE is -0.01%, compared to INSP's ROE of +0.18%. Regarding short-term risk, AORT is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for AORT.Check INSP's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while TNDM trades at $22.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas TNDM's P/E ratio is -20.35. In terms of profitability, AORT's ROE is -0.01%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, AORT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TNDM's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ENOV trades at $26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ENOV's P/E ratio is 7.62. In terms of profitability, AORT's ROE is -0.01%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, AORT is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ENOV's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CNMD trades at $49.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CNMD's P/E ratio is 10.78. In terms of profitability, AORT's ROE is -0.01%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, AORT is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CNMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ATEC trades at $9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ATEC's P/E ratio is -155.17. In terms of profitability, AORT's ROE is -0.01%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, AORT is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ATEC's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while IART trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas IART's P/E ratio is 7.31. In terms of profitability, AORT's ROE is -0.01%, compared to IART's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for AORT.Check IART's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AORT's ROE is -0.01%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AORT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HSKA's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while IRMD trades at $92.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas IRMD's P/E ratio is 46.48. In terms of profitability, AORT's ROE is -0.01%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, AORT is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check IRMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas AVNS's P/E ratio is 27.77. In terms of profitability, AORT's ROE is -0.01%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AORT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AVNS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PRCT trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PRCT's P/E ratio is -10.52. In terms of profitability, AORT's ROE is -0.01%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, AORT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PRCT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SILK's P/E ratio is -18.96. In terms of profitability, AORT's ROE is -0.01%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AORT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SILK's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while LMRI trades at $11.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas LMRI's P/E ratio is -22.53. In terms of profitability, AORT's ROE is -0.01%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, AORT is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check LMRI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas FNA's P/E ratio is -19.83. In terms of profitability, AORT's ROE is -0.01%, compared to FNA's ROE of -0.35%. Regarding short-term risk, AORT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check FNA's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BVS trades at $14.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BVS's P/E ratio is 18.59. In terms of profitability, AORT's ROE is -0.01%, compared to BVS's ROE of +0.28%. Regarding short-term risk, AORT is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BVS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, INMD has a market cap of 880M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while INMD trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas INMD's P/E ratio is 10.63. In terms of profitability, AORT's ROE is -0.01%, compared to INMD's ROE of +0.13%. Regarding short-term risk, AORT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check INMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while AVR trades at $8.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas AVR's P/E ratio is -4.00. In terms of profitability, AORT's ROE is -0.01%, compared to AVR's ROE of -1.24%. Regarding short-term risk, AORT is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AVR's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CSII's P/E ratio is -20.83. In terms of profitability, AORT's ROE is -0.01%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AORT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CSII's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SIBN trades at $18.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SIBN's P/E ratio is -54.74. In terms of profitability, AORT's ROE is -0.01%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, AORT is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SIBN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while AHCO trades at $5.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas AHCO's P/E ratio is 11.61. In terms of profitability, AORT's ROE is -0.01%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, AORT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for AORT.Check AHCO's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SSII trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SSII's P/E ratio is -73.53. In terms of profitability, AORT's ROE is -0.01%, compared to SSII's ROE of -0.23%. Regarding short-term risk, AORT is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SSII's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BBNX trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BBNX's P/E ratio is -10.53. In terms of profitability, AORT's ROE is -0.01%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, AORT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BBNX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CBLL trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CBLL's P/E ratio is -11.54. In terms of profitability, AORT's ROE is -0.01%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, AORT is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CBLL's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while TCMD trades at $29.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas TCMD's P/E ratio is 33.52. In terms of profitability, AORT's ROE is -0.01%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check TCMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AORT's ROE is -0.01%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, AORT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SRDX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BWAY trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BWAY's P/E ratio is 39.38. In terms of profitability, AORT's ROE is -0.01%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, AORT is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BWAY's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while KIDS trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas KIDS's P/E ratio is -19.30. In terms of profitability, AORT's ROE is -0.01%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, AORT is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check KIDS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas APEN's P/E ratio is -9.43. In terms of profitability, AORT's ROE is -0.01%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AORT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check APEN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CTKB trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CTKB's P/E ratio is -22.25. In terms of profitability, AORT's ROE is -0.01%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, AORT is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CTKB's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AORT's ROE is -0.01%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ZIMV's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while VREX trades at $12.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas VREX's P/E ratio is 13.06. In terms of profitability, AORT's ROE is -0.01%, compared to VREX's ROE of -0.18%. Regarding short-term risk, AORT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check VREX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while DCTH trades at $15.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, AORT's ROE is -0.01%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, AORT is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for AORT.Check DCTH's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while NPCE trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas NPCE's P/E ratio is -25.57. In terms of profitability, AORT's ROE is -0.01%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, AORT is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for AORT.Check NPCE's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CERS trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CERS's P/E ratio is -46.91. In terms of profitability, AORT's ROE is -0.01%, compared to CERS's ROE of -0.10%. Regarding short-term risk, AORT is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CERS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CLPT trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CLPT's P/E ratio is -12.04. In terms of profitability, AORT's ROE is -0.01%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, AORT is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CLPT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while OFIX trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas OFIX's P/E ratio is -13.43. In terms of profitability, AORT's ROE is -0.01%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, AORT is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check OFIX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SGHT trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SGHT's P/E ratio is -13.34. In terms of profitability, AORT's ROE is -0.01%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, AORT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SGHT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CARL trades at $13.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CARL's P/E ratio is -9.66. In terms of profitability, AORT's ROE is -0.01%, compared to CARL's ROE of -0.38%. Regarding short-term risk, AORT is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CARL's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PACB has a market cap of 368.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PACB trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PACB's P/E ratio is -2.89. In terms of profitability, AORT's ROE is -0.01%, compared to PACB's ROE of -49.62%. Regarding short-term risk, AORT is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PACB's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CV trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CV's P/E ratio is -2.84. In terms of profitability, AORT's ROE is -0.01%, compared to CV's ROE of +1.27%. Regarding short-term risk, AORT is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CV's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PMI trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PMI's P/E ratio is -2.83. In terms of profitability, AORT's ROE is -0.01%, compared to PMI's ROE of +4.99%. Regarding short-term risk, AORT is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PMI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ELMD trades at $42.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ELMD's P/E ratio is 35.97. In terms of profitability, AORT's ROE is -0.01%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, AORT is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ELMD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while CATX trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas CATX's P/E ratio is -2.13. In terms of profitability, AORT's ROE is -0.01%, compared to CATX's ROE of -0.42%. Regarding short-term risk, AORT is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CATX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AORT's ROE is -0.01%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, AORT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SMLR's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while TMCI trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas TMCI's P/E ratio is -5.06. In terms of profitability, AORT's ROE is -0.01%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, AORT is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TMCI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while SENS trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas SENS's P/E ratio is -3.51. In terms of profitability, AORT's ROE is -0.01%, compared to SENS's ROE of -1.66%. Regarding short-term risk, AORT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SENS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ANIK trades at $21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ANIK's P/E ratio is 43.71. In terms of profitability, AORT's ROE is -0.01%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, AORT is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ANIK's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while PROF trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas PROF's P/E ratio is -5.98. In terms of profitability, AORT's ROE is -0.01%, compared to PROF's ROE of -0.56%. Regarding short-term risk, AORT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PROF's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while RXST trades at $6.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas RXST's P/E ratio is -6.73. In terms of profitability, AORT's ROE is -0.01%, compared to RXST's ROE of -0.17%. Regarding short-term risk, AORT is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for AORT.Check RXST's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas MGRM's P/E ratio is -12.00. In terms of profitability, AORT's ROE is -0.01%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, AORT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for AORT.Check MGRM's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while FOCL trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas FOCL's P/E ratio is -8.00. In terms of profitability, AORT's ROE is -0.01%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, AORT is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for AORT.Check FOCL's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AORT's ROE is -0.01%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AORT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NVRO's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while TLSI trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas TLSI's P/E ratio is -3.34. In terms of profitability, AORT's ROE is -0.01%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, AORT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TLSI's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while RCEL trades at $7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas RCEL's P/E ratio is -4.95. In terms of profitability, AORT's ROE is -0.01%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, AORT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for AORT.Check RCEL's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AORT's ROE is -0.01%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, AORT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BSGM's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while QTRX trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas QTRX's P/E ratio is -2.52. In terms of profitability, AORT's ROE is -0.01%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, AORT is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check QTRX's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AORT's ROE is -0.01%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AORT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check MDGS's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, STIM has a market cap of 165.6M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while STIM trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas STIM's P/E ratio is -4.41. In terms of profitability, AORT's ROE is -0.01%, compared to STIM's ROE of -1.65%. Regarding short-term risk, AORT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check STIM's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while INGN trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas INGN's P/E ratio is -6.65. In terms of profitability, AORT's ROE is -0.01%, compared to INGN's ROE of -0.13%. Regarding short-term risk, AORT is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for AORT.Check INGN's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AORT's ROE is -0.01%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AORT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check QIPT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas ICAD's P/E ratio is -20.37. In terms of profitability, AORT's ROE is -0.01%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, AORT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ICAD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while OWLT trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas OWLT's P/E ratio is -39.43. In terms of profitability, AORT's ROE is -0.01%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, AORT is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check OWLT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while LUCD trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas LUCD's P/E ratio is -2.61. In terms of profitability, AORT's ROE is -0.01%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, AORT is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check LUCD's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while HSDT trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas HSDT's P/E ratio is -0.02. In terms of profitability, AORT's ROE is -0.01%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, AORT is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HSDT's competition here

Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AORT stands at 1.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, AORT is priced at $27.12 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AORT currently has a P/E ratio of 45.28, whereas HJLI's P/E ratio is N/A. In terms of profitability, AORT's ROE is -0.01%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, AORT is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HJLI's competition here